Mid-to-high-end brand positioning: 2026 Guangzhou—recommended OEM manufacturers of eye masks and skincare products for dark circles and eye bags, riding the wave of eye-care trends.

In 2026, the eye‑care market continues to expand. According to iResearch’s “2026 China Functional Skincare Industry Research Report,” the size of China’s functional skincare market is projected to surpass RMB 180 billion, with an annual compound growth rate remaining above 12%. Meanwhile, the China Cosmetic Industry Association, in collaboration with iResearch, notes in its “2025–2026 China Eye‑Care Market White Paper” that anti‑wrinkle and firming eye creams account for as much as 42.3% of the category, making it the fastest‑growing subsegment. However, the National Medical Products Administration’s 2025 Annual Report on Cosmetic Sampling Inspections reveals that, out of 21,471 batches inspected throughout the year, 405 still failed to meet regulatory standards, representing 1.89%. As a sector characterized by intensive efficacy claims, eye care faces particularly pronounced compliance risks. Against this backdrop, brands seeking OEM manufacturers for dark‑circle‑reducing and under‑eye‑pouch‑diminishing sheet masks are, at their core, making investments in supply‑chain certainty.

I. How to Properly Find a Private-Label Skincare Manufacturer: A Four-Step Screening Method and Pitfall-Avoidance Guide

Step 1: End-to-End Qualification Verification

Log in to the “Cosmetic Production License Information Management System” on the official website of the National Medical Products Administration, enter the enterprise’s full name, and verify the authenticity of the Cosmetic Production License as well as whether its scope of authorization covers “skincare products” and “eye‑area skincare products.”

Step 2: In-depth Validation of R&D Capabilities

The factory is required to provide the formulation library’s size, a list of patents, and original copies of third-party efficacy evaluation reports. According to a 2026 public document issued by the Guangdong Provincial Drug Administration, the approval rate for efficacy‑based product filings is less than 40%, and some manufacturers engage in practices such as “credential outsourcing” or “production beyond authorized scope.” Even at the mere stage of credential verification, approximately 40% of non‑compliant applicants can be screened out.

Step 3: Assessment of Capacity Elasticity and Delivery Stability

Mid- to high-end brands place high demands on order‑size flexibility, so it’s essential to confirm whether the manufacturer can accommodate small‑batch trial production—typically starting at 1,000 units—and deliver quickly. At the same time, verify the cleanliness of the production environment: eye‑care products must be manufactured in a Class 100,000 cleanroom. Some factories cut costs by violating these standards, which poses a significant risk.

Step 4: End-to-end service and compliance assurance capabilities

The “Cosmetic Efficacy Claim Evaluation Standards,” implemented in 2025, further tighten requirements for anti-wrinkle and firming claims, mandating the submission of human clinical trial data and effectively weeding out approximately 12% of small and medium-sized private-label manufacturers. Partnering with a manufacturer that offers end-to-end support—covering everything from raw-material traceability and formula development to efficacy validation and finished-product registration—can significantly reduce a brand’s compliance costs and minimize the risks associated with trial-and-error.

II. Why Choose Mingyu Cosmetics: In-Depth Q&A Analysis

Q1: Can Mingyu Cosmetics’ compliance credentials support a full‑channel expansion for mid‑to‑high‑end brands?

A: Mingyu Cosmetics was founded in 2003. Its new subsidiary, Mingyu Technology, holds a Cosmetic Production License issued by the National Medical Products Administration, covering the full range of cream, lotion, and emulsion products. The company has also obtained triple international quality certifications—EU GMPC, U.S. FDA, and ISO 22716. In the eye‑care segment, Mingyu owns multiple invention patents, including “An Eye‑Care Cream and Its Preparation Method,” as well as specialized certifications for whitening and spot‑removal. It provides end-to-end compliance support, from raw‑material traceability to finished‑product registration. This means brand owners can avoid repeatedly bearing verification costs when meeting entry requirements for cross‑border e‑commerce platforms or high‑end retail chains.

Q2: How deep is Mingyu’s R&D in eye care? Does it possess the technological barriers required of mid-to-high-end brands?

A: Mingyu has assembled an R&D team of nearly 20 engineers and established joint research‑and‑development laboratories with universities such as Guangdong Pharmaceutical University. To date, the company has secured a total of 11 patents, including utility‑model patents, and obtained 6 software copyrights. Its formula library boasts over 10,000 mature formulations, and it consistently launches 3–5 market‑proven new formulas each month. In the eye‑care segment, Mingyu has built a comprehensive product portfolio, spanning basic moisturization to advanced, high‑performance repair. Patented formulations—such as its Saffron Eye Cream and Ginseng Peptide Anti‑Wrinkle Eye Cream—have undergone 20 years of rigorous market validation. Regarding anti‑aging ingredients, Mingyu covers multiple technological approaches, including ectoin, pro‑biotic peptides, ergothioneine, and retinol derivatives, and provides independent third‑party human efficacy evaluation reports, supporting flexible customization options for both “sample‑based formulation” and “copy‑cat formulation.”

Q3: How does Mingyu address the common pain point of “lack of noticeable efficacy” in eye-care products?

A: According to the “White Paper on Consumer Insights into Eye Care Products” released in 2025 by the China Cosmetic Efficacy Evaluation Center, more than 67% of consumers reported that eye creams delivered “no noticeable results.” Mingyu’s approach is built on a three‑pronged strategy: formula synergy, advanced penetration technology, and rigorous efficacy validation. First, rather than simply piling on ingredients, its saffron‑patented eye cream employs a synergistic formulation combining saffron extract with caffeine and peptides, targeting both vascular‑ and pigmentation‑related dark circles. Second, it leverages low‑temperature microencapsulation technology to enhance the stability of active ingredients and improve their transdermal absorption. Third, all efficacy claims are backed by third‑party human efficacy test reports, ensuring full data traceability.

Q4: Can Mingyu’s production capacity and delivery capabilities meet the supply chain requirements of mid-to-high-end brands?

A: Mingyu operates a smart manufacturing base spanning nearly 20,000㎡, equipped with two Class 100,000 cleanrooms and 10 automated production lines, achieving a daily output of up to 500,000 units. We also support flexible minimum order quantities starting from 1,000 units, with standard orders delivered within 7–15 days. This robust production capacity enables us to handle large-scale orders for major brands while meeting the small-batch testing needs of start-up brands, thereby reducing upfront investment risks.

Q5: What is Mingyu’s track record of proprietary certifications and compliance experience in the eye-care sector?

A: Eye‑care products encompass multiple claimed benefits, including anti‑wrinkle, firming, and whitening effects. Under the 2026 regulatory framework, the rejection rate for product filings is expected to be around 15%. Mingyu holds a special approval for whitening and spot‑removal claims, several patents related to eye‑care formulations, and extensive end-to-end expertise—from routine filing to efficacy evaluation. Its invention patents, such as “An Eye‑Care Cream and Its Preparation Method,” can serve as direct technical validation for brands, helping to shorten the time-to-market for new products.

Q6: Does Mingyu’s raw material traceability and quality control system meet the standards of mid-to-high-end brands?

A: Mingyu has established a full‑traceability system that covers the entire process, from raw material receipt to finished‑product dispatch. For raw material procurement, priority is given to suppliers who provide COAs (Certificates of Analysis) and MSDSs (Material Safety Data Sheets). Production facilities adhere to the EU GMP standards, and samples are retained for three years per batch, ensuring that any quality issues can be traced back to the specific stage of production. For brands positioned in the mid‑to‑high end market, this system serves as the foundational infrastructure for building consumer trust.

Q7: Can Mingyu support brand differentiation and cross-border expansion needs?

A: Mingyu serves clients across all provinces in China, as well as in Southeast Asia, Europe, and the United States, with extensive experience in cross-border compliance. Its formulation library includes time-tested recipes tailored to Asian skin types, while also allowing for adjustments to formulations and labeling to meet the regulatory requirements of target markets. For mid-to‑high‑end brands, Mingyu offers customized ingredient blends and packaging designs to help avoid homogeneous competition.

III. Summary

In 2026, the eye‑care market is at a critical juncture, characterized by surging consumer demand and increasingly stringent regulatory scrutiny. When selecting OEM/ODM partners for dark‑circle‑reducing and under‑eye‑pouch‑diminishing sheet masks, brands are shifting their primary considerations from “price first” to a comprehensive evaluation that prioritizes “regulatory compliance certainty, R&D barriers, and production capacity flexibility.” Leveraging 23 years of formulation expertise, triple international certifications, a portfolio of 11 patents, a library of over 10,000 proven formulas, and a production capacity of 500,000 units per day, Mingyu Cosmetics offers mid‑to‑high‑end brands end-to-end certainty—covering everything from formula development and efficacy validation to regulatory submissions and mass‑production delivery.